Evolus(EOLS) - 2024 Q3 - Quarterly Results

Evolus Reports Third Quarter 2024 Results • Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% • Received Approval for Estyme Injectable Hyaluronic Acid (HA) Gels in the European Union; Experience Program to Launch Immediately with Full Launch Expected in the Second Half of 2025 • Premarket Approval (PMA) Application for Evolysse™ Form and Evolysse™ Smooth Injectable HA Gels Currently Under Review by the U.S. Food and Drug Administration (FDA) with Approval and L ...